Related Experiment Video
Updated: Jun 22, 2026
07:41
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Valproic acid exerts differential effects on CXCR4 expression in leukemic cells
Hilal Gul1, Leah A Marquez-Curtis, Nadia Jahroudi
1Canadian Blood Services R & D, Edmonton, Alberta, Canada; Department of Medicine, University of Alberta, Edmonton, Alberta T6G 2R8, Canada.
Leukemia Research
|June 23, 2009
Summary
Valproic acid (VPA) differentially affects CXCR4 in acute myeloid leukemia (AML) cells. VPA decreases CXCR4 in immature AML cells but increases it in more mature subtypes, impacting AML treatment strategies.
Area of Science:
- Hematology
- Molecular Biology
- Cancer Research
Background:
- Valproic acid (VPA), a histone deacetylase inhibitor, has been shown to increase CXCR4 in hematopoietic stem/progenitor cells (HSPC) and immature AML cell lines.
- CXCR4 receptor expression is crucial for leukemia cell trafficking and survival.
Purpose of the Study:
- To investigate the effect of VPA on CXCR4 expression and function in CD34-negative AML cell lines and primary AML cells.
- To determine if VPA's impact on CXCR4 varies with AML cell maturation status.
Main Methods:
- Treatment of CD34-negative AML cell lines (HL-60, THP-1) and primary AML cells (CD34-positive and CD34-negative) with VPA.
- Assessment of CXCR4 expression and chemotaxis.
Main Results:
- VPA diminished CXCR4 expression and chemotaxis in HL-60 cells and CD34-negative primary AML cells.
- VPA increased CXCR4 expression and function in highly CD34-positive primary AML cells.
Conclusions:
- VPA exerts differential effects on CXCR4 based on AML cell maturation status.
- These findings suggest novel therapeutic strategies for AML by modulating CXCR4 with VPA.
